Search details
1.
High-dose chemotherapy and peripheral blood stem cell transplantation as salvage therapy in primary mediastinal nonseminomatous germ cell tumors: The Indiana University experience.
Cancer
; 2024 May 20.
Article
in English
| MEDLINE | ID: mdl-38768296
2.
Dipeptidyl Peptidase 4 Inhibition for Prophylaxis of Acute Graft-versus-Host Disease.
N Engl J Med
; 384(1): 11-19, 2021 01 07.
Article
in English
| MEDLINE | ID: mdl-33406328
3.
Impact of prior lenalidomide or proteasome inhibitor exposure on the effectiveness of ixazomib-lenalidomide-dexamethasone for relapsed/refractory multiple myeloma: A pooled analysis from the INSURE study.
Eur J Haematol
; 2024 Apr 23.
Article
in English
| MEDLINE | ID: mdl-38654611
4.
In-class transition from bortezomib-based therapy to IRd is an effective approach in newly diagnosed multiple myeloma.
Future Oncol
; 20(3): 131-143, 2024 Jan.
Article
in English
| MEDLINE | ID: mdl-37807952
5.
Survival outcomes and toxicity in patients 40 years old or older with relapsed metastatic germ cell tumors treated with high-dose chemotherapy and peripheral blood stem cell transplantation.
Cancer
; 127(20): 3751-3760, 2021 10 15.
Article
in English
| MEDLINE | ID: mdl-34260067
6.
Effect of initial treatment on health-related quality of life in patients with newly diagnosed multiple myeloma without immediate stem cell transplant intent: results from the Connect® MM Registry.
Br J Haematol
; 193(1): 93-100, 2021 04.
Article
in English
| MEDLINE | ID: mdl-33118614
7.
Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US.
Ann Hematol
; 100(9): 2325-2337, 2021 Sep.
Article
in English
| MEDLINE | ID: mdl-33970288
8.
Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma.
Future Oncol
; 17(19): 2499-2512, 2021 Jul.
Article
in English
| MEDLINE | ID: mdl-33769076
9.
High-dose chemotherapy plus peripheral blood stem cell transplantation for patients with relapsed germ cell tumors and active brain metastases.
Cancer
; 126(6): 1202-1207, 2020 03 15.
Article
in English
| MEDLINE | ID: mdl-31743434
10.
Association between race and treatment patterns and survival outcomes in multiple myeloma: A Connect MM Registry analysis.
Cancer
; 126(19): 4332-4340, 2020 10 01.
Article
in English
| MEDLINE | ID: mdl-32706404
11.
Development of a prognostic model for overall survival in multiple myeloma using the Connect® MM Patient Registry.
Br J Haematol
; 187(5): 602-614, 2019 12.
Article
in English
| MEDLINE | ID: mdl-31382320
12.
Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect® MM Registry.
Ann Hematol
; 97(12): 2425-2436, 2018 Dec.
Article
in English
| MEDLINE | ID: mdl-30056582
13.
Cancer-related loneliness mediates the relationships between social constraints and symptoms among cancer patients.
J Behav Med
; 41(2): 243-252, 2018 04.
Article
in English
| MEDLINE | ID: mdl-28983735
14.
Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma.
Blood
; 126(20): 2284-90, 2015 Nov 12.
Article
in English
| MEDLINE | ID: mdl-26384354
15.
Recognition of early mortality in multiple myeloma by a prediction matrix.
Am J Hematol
; 92(9): 915-923, 2017 Sep.
Article
in English
| MEDLINE | ID: mdl-28543165
16.
The Cancer Loneliness Scale and Cancer-related Negative Social Expectations Scale: development and validation.
Qual Life Res
; 26(7): 1901-1913, 2017 07.
Article
in English
| MEDLINE | ID: mdl-28236266
17.
American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma.
Biol Blood Marrow Transplant
; 21(12): 2039-2051, 2015 Dec.
Article
in English
| MEDLINE | ID: mdl-26428082
18.
A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma.
Blood
; 120(22): 4324-33, 2012 Nov 22.
Article
in English
| MEDLINE | ID: mdl-23033266
19.
1q amplification and PHF19 expressing high-risk cells are associated with relapsed/refractory multiple myeloma.
Nat Commun
; 15(1): 4144, 2024 May 16.
Article
in English
| MEDLINE | ID: mdl-38755140
20.
Real-World Utilization of Radiation Therapy in Multiple Myeloma: An Analysis of the Connect MM Registry.
Pract Radiat Oncol
; 14(2): e141-e149, 2024.
Article
in English
| MEDLINE | ID: mdl-37984714